August 10, 2022

Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility

Sen. Hassan toured the company’s U.S. headquarters in Portsmouth before meeting and speaking with employees ROOT, Switzerland–(BUSINESS WIRE)–On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure’s groundbreaking… Read More
learn more
July 27, 2022

Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Awards aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies ROOT, Switzerland–(BUSINESS WIRE)–Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating… Read More
learn more
July 1, 2022

Novocure to Report Second Quarter 2022 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss the company’s financial results for the three and… Read More
learn more
June 21, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treating Fields… Read More
learn more
June 3, 2022

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to… Read More
learn more
May 26, 2022

Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of… Read More
learn more
April 28, 2022

Novocure Reports First Quarter 2022 Financial Results

Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a global oncology company working to extend… Read More
learn more
April 19, 2022

Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu

Governor Sununu and Novocure leadership delivered keynote remarks, celebrating the construction of Novocure’s new flagship facility in Portsmouth, NH ST. HELIER, Jersey–(BUSINESS WIRE)–Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown… Read More
learn more
April 8, 2022

Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022. The research described in the presentations spans… Read More
learn more
April 1, 2022

Novocure to Report First Quarter 2022 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three months ended… Read More
learn more